In the case of CD151, a series of in vitro and in vivo studies reveal a strong inhibitory effect of CD151 downregulation or deletion on tumor onset and growth in either ErbB2+ or basal-like subtypes [29,32,38,71,86]. The gene discussed is ERBB2; the disease is neoplasm.